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Abstract
Background: Hepatitis A virus (HAV) is a causative agent of acute hepatitis, which is transmitted by person-to-
person contact and via the faecal-oral route. Acute HAV infection is usually confirmed by anti-HAV IgM detection.
In order to detect anti-HAV IgM in the serum of patients infected with HAV, we developed a rapid assay based on
immunochromatography (ICA) and evaluated the sensitivity of this assay by comparing it with a commercial
microparticle enzyme immunoassay (MEIA) that is widely used for serological diagnosis.
Results: The newly developed ICA showed 100% sensitivity and specificity when used to test 150 anti-HAV IgM-
positive sera collected from infected patients and 75 negative sera from healthy subjects. Also, the sensitivity of ICA
is about 10 times higher than MEIA used in this study by determining end point to detect independent on
infected genotype of HAV. In addition, the ICA was able to detect 1 positive sample from among 50 sera from
acute hepatitis patients that had tested negative for anti-HAV IgM using the MEIA.
Conclusion: Conclusively, ICA for the detection of anti-HAV IgM will be very effective for rapid assay to apply
clinical diagnosis and epidemiological investigation on epidemics due to the simplicity, rapidity and specificity.
Background
Hepatitis A virus (HAV) is one of the common causative
agents of acute hepatitis worldwide [1]. The clinical man-
ifestation of HAV infection in humans can vary greatly,
ranging from asymptomatic infection to fulminant hepa-
titis [2,3]. As a result of improvements in public sanita-
tion and hygiene conditions, there has been a striking
reduction in HAV endemicity in Western countries over
the past few decades [4,5]. The shift from high to inter-
mediate or low endemicity leads to a change in the age of
individuals susceptible to hepatitis A, from children to
adolescents or adults. In general, infection during child-
hood is asymptomatic, whereas infection in adults is
often more severe. The standard diagnosis of acute hepa-
titis A is based on the detection of the immunoglobulin
M (IgM) antibody to HAV (HAV-IgM) in patients who
present with clinical features of hepatitis. Nevertheless,
since many cases of hepatitis A are asymptomatic, HAV-
IgM can be found in individuals who do not have clinical
symptoms or biological abnormalities [6]. IgM antibodies
directed against specific viral antigens can be detected
due to nonspecific polyclonal activation of memory cells
from a previous infection with an unrelated agent.
Immune cells may become activated during viral infec-
tions or immune diseases [7-12]. Thus, in some cases,
anti-HAV IgM detection could also correspond to
immune reactivation.
The incubation period for HAV is from 2 to 6 weeks
[13]. Anti-HAV IgM and IgG are detectable at the onset
of symptoms [14], although virus can be detected in the
blood and faeces sooner (10 to 12 days post-infection).
Anti-HAV IgM continues to be detected in infected
individuals for between 2 and 9 months post-infection
[15], after which it declines. Therefore, anti-HAV IgM is
useful for diagnosing acute or recent infection. Further,
a diagnostic assay with high sensitivity for the detection
of IgM is considered to be a valuable tool for the timely
care of patients and for the control of infection during
HAV epidemics in large population communities,
including schools and military camps.
The anti-HAV IgG antibody increases gradually,
reaching high levels during the convalescent phase [16]
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fection. Secretory IgA is associated with intestinal resis-
tance to many viral infections, as in the case of the
polioviruses. The oral vaccine, obtained from attenuated
viral strains, induces the production of this antibody
and protects against enteric reinfection. In spite of this,
some authors have shown that in cases of infection by
HAV, intestinal immunity does not represent protection
against this virus [14]. The routine laboratory diagnosis
performed in cases of hepatitis A involves measuring
the serum levels of intracellular hepatic enzymes (ALT
and AST) as well as the detection of anti-HAV IgM
antibodies in blood samples [17].
In this study, we developed an immunochromato-
graphic assay for the detection of anti-HAV IgM and
applied this to clinical specimens in order to determine
the sensitivity and usefulness of this assay compared
with a chemiluminescent-linked immunoassay that is
widely used for the routine diagnosis of HAV infection.
Results
Sensitivity and specificity of the ICA compared with the
MEIA
By using the ICA devised in this investigation, we were
able detect anti-HAV IgM in 150 sera from patients
with acute viral hepatitis (confirmed as recent HAV
infections), who were infected by 1 of 3 different HAV
genotypes. Further, anti-HAV IgM was not detected in
75 sera collected from normal subjects. In the testing of
these sera, the ICA showed 100% sensitivity and specifi-
city (Table 1). Among the 50 serum samples shown to
be negative for anti-HAV IgM using the commercial
MEIA, the presence of anti-HAV IgM was detected in 1
sample using the newly developed ICA.
Comparison of assay sensitivity by determining the end-
point detection limit
The ICA developed in this investigation could detect
anti-HAV IgM from 10
-1 to 10
-4 dilutions of all tested
serum; however, the “T” band of the ICA showed
differing intensities with the 10
-4 dilutions according to
the different HAV genotypes. In the serum from
patients infected with HAV genotype IA, anti-HAV IgM
was strongly detected in the 10
-4 serum dilution,
whereas IgM was weakly detected in the 10
-4 dilutions
of serum collected from patients infected with HAV
genotypes IIIA and IB. Using the MEIA, we could detect
IgM down to a dilution of 10
-3, but could not detect it
in the 10
-4 dilutions (Table 2).
Discussion
In order to detect anti-HAV IgM in the serum of
patients with HAV infection, we developed a diagnostic
assay based on immunochromatography and evaluated
the sensitivity of this assay using clinical specimens by
comparing with an MEIA (AxSYM HAVAB-M 2.0). The
sensitivity and specificity for anti-HAV IgM were both
100% in each of the 2 assays, as determined by the assay
of 150 positive and 75 negative samples. However,
among the 50 serum samples shown to be negative for
anti-HAV IgM using the commercial MEIA, 1 sample
was confirmed positive for anti-HAV IgM using the
newly developed ICA. Although this specimen was con-
sidered to be negative based on optical density readings
using the reagents supplied by the manufacturer, it has
significant amount anti-HAV IgM less than cut off
index (COI) (COI < 1.0) by MEIA. This suggests that
the inconsistency between the 2 assays is attributable to
their respective sensitivities.
Surprisingly, although we used only 5 μlo fs e r af o r
the ICA, the sensitivity of the ICA was approximately
10 times higher than that of the MEIA used in this
study based on a determination of the end-point detec-
tion limit independent of HAV genotype.
Table 1 Comparison of ICA and MEIA (AxSYM HAVAB-M 2.0)
ICA developed in this
study
MEIA
(AxSYM HAVAB-
M 2.0)
+- + -
HAV patients
(genotypes IA, IIIA, and IB)
(n
a = 150)
150 0 150 0
Patients with hepatitis
symptom (n = 50)
14 9 0 5 0
Normal subjects
(n = 75)
07 5 0 7 5
a number of sample
Table 2 Detection of anti-HAV IgM in 10-fold serial
dilutions of serum using ICA (SD Rapid test) and MEIA
(AxSYM HAVAB-M 2.0)
Genotype ICA developed in this study MEIA (COI)
10
-2 10
-3 10
-4 10
-5 10
-2 10
-3 10
-4 10
-5
IA-1 ++ ++ ++ - +
(5.21)
+
(1.55)
-
(0.46)
-
(0.37)
IA-2 ++ ++ ++ - +
(5.14)
+
(1.78)
-
(0.49)
-
(0.36)
IIIA-1 ++ ++ + - +
(5.95)
+
(1.76)
-
(0.48)
-
(0.43)
IIIA-2 ++ ++ + - +
(4.72)
+
(1.35)
-
(0.56)
-
(0.31)
IB-1 ++ ++ + - +
(4.35)
+
(1.25)
-
(0.37)
-
(0.29)
IB-2 ++ ++ + - +
(4.58)
+
(1.01)
-
(0.38)
-
(0.29)
(ICA: ++ strong positive, + weak positive, - negative)
(MEIA: + positive, - negative, COI negative > 1 > positive)
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appearance of anti-IgM after HAV infection, timely
medical care for patients with acute hepatitis and an
effective control strategy during HAV-related epidemics
in the community tend to be delayed [18]. Especially,
earlier diagnosis based on higher sensitivity for close
contact person without clinical symptoms among popu-
lation with HAV epidemic can provide effective measure
for determining strategy to stop spreading infections in
community.
Although the MEIA using an automated system for
general serological diagnosis can provide sensitive
results compared other serologic assays, including the
ELISA and rapid immunoassays reported previously, it
involves the use of expensive equipment, and can be
costly and relatively time-consuming when handling
large sample sizes, as in an epidemic.
Therefore, many investigators have reported rapid ser-
ological assays for the detection of anti-HAV antibodies.
One such assay is the dot immunogold filtration assay
(DIGFA) for the detection of IgM antibody [19]. This
assay does not require expensive laboratory equipment,
and the sensitivity and specificity of this test have been
shown to be 91.3% and 96.0%, respectively. However,
both the sensitivity and specificity for anti-HAV IgM in
DIGFA are lower than in the MEIA (AxSYM HAVAB-
M 2.0).
In our study, the sensitivity of the ICA for anti-HAV
IgM was demonstrated to be higher than that of the
MEIA. In addition, performance of the ICA requires
only a simple test kit without other detection equip-
ment; therefore, the assay does not need expensive
laboratory equipment or large amounts of space, as does
DIGFA.
Synthetic peptides have also been used for the detec-
tion of HAV antibodies using biosensor technology
based on surface plasmon resonance [20]. Using this
system, a sensitivity range of 48% to 96% was achieved,
the degree of sensitivity depending upon which peptide
was used.
Even though this assay is in the developmental stage,
biosensors can be more rapid than EIAs when they are
fully automated and have potential clinical value; how-
ever, their expense may prove prohibitive [20]. In con-
trast, the ICA showed a high sensitivity comparable to
MEIA; moreover, its use is not limited by relatively high
costs.
However, although there was no significant difference
in the specificities of the ICA and MEIA, the sensitivity
of the ICA for HAV in sera was higher than that of the
MEIA based on the end-point detection of antibody and
the ability to detect anti-HAV IgM in samples that test
negative using the MEIA. Owing to its rapidity and spe-
cificity, the ICA can be used as an effective assay for
screening HAV infection. It takes less than 20 minutes
to complete the assay, whereas the MEIA takes approxi-
mately 30 minutes. The shorter reaction time in the
ICA does not influence its sensitivity and specificity.
There is, however, a significant difference in the cost of
the ICA and AxSYM HAVAB-M 2.0 systems. When
assaying using the AxSYM HAVAB-M 2.0, expensive
laboratory equipment, several regents, reagent vessels,
matrix cells, and a sample cup are required. In addition,
the AxSYM HAVAB-M 2.0 requires a certain amount of
space for the necessary laboratory equipment. However,
when assaying using the ICA developed in this study,
we need only a simple test kit and a single reagent for
diffusion. This means that the cost of detecting anti-
HAV IgM using the ICA is considerably less than when
using the AxSYM HAVAB-M 2.0.
Conclusions
In conclusion, ICA can detect anti-HAV IgM effectively
and use of this system without the help of extra appara-
tus enables to detect and screen HAV infection easily
and rapidly, which can be widely used in an epidemiolo-
gical survey.
Methods
Serum samples
All samples were obtained with informed consent and
approval of the KCDC Institutional Review Board (IRB).
One hundred and fifty serum samples were collected
from patients with acute hepatitis who had HAV infec-
tion confirmed by serological diagnostic methods and
molecular analysis for the determination of the infecting
HAV genotype. Among the 150 sera, we identified 70
(46.7%) as being infected with genotype IA, 77 (51.3%)
infected with IIIA, and 3 (2.0%) infected with IB (data
not shown). As negative controls, 75 sera were also
obtained from healthy individuals confirmed as having
no recent HAV infection. Additionally, 50 serum sam-
ples were collected from patients with illness compatible
with HAV infection but in whom the anti-HAV IgM
had not been detected. We stored serum specimens at
-70°C until use, and for the serological assays we used 5
μlo fs e r u mf o rt h eI C Aa n d1 5 0μlo fs e r u mf o rt h e
MEIA.
Detection of anti-HAV IgM using the
immunochromatographic assay
The ICA is designed for the detection of anti-HAV IgM
in human serum or plasma. The ICA device has 2 pre-
coated lines–“T” (an HAV IgM line coated with anti-
human IgM) and “C” (a control line coated with goat
anti-mouse IgG)–on the surface of the membrane. Puri-
fied HAV antigens and colloidal gold-conjugated HAV-
specific monoclonal antibody were dried on a pad. The
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tion of anti-HAV IgM was performed strictly according
to instructions. Briefly, 5 μl of serum or plasma drawn
to black line into the square sample well marked “S” for
sample inlet. Four drops of diluent containing 0.1 M
phosphate buffer, 0.1% Tween 20, and 0.01% sodium
azide was then introduced into the sample inlet and the
test results were interpreted within 20 minutes.
The results were interpreted as follows. The control
line should always appear in order to obtain a valid
result for diagnosis–this indicates that the procedure
has been performed correctly. If a purple “T” line is visi-
ble in the result window, a positive result is confirmed–
this indicates that level of the anti-HAV IgM in the
sample is above the detection limit. Otherwise, we con-
firm a negative result.
Detection of anti-HAV IgM by the MEIA
AxSYM HAVAB-M 2.0 (Abbott Laboratory, USA) is
based on microparticle enzyme immunoassay technol-
ogy. The samples and all the AxSYM HAVAB-M 2.0
reagents required for one test were pipetted with the
sampling probe into wells in the reaction vessel of the
sampling centre. The reaction vessel was immediately
transferred to the processing centre. Further pipetting
was conducted in the processing centre using the pro-
cessing probe. All steps were performed automatically
and the diagnostic results were reported immediately.
The AxSYM HAVAB-M 2.0 system includes the follow-
ing: an antibody to human IgM (goat)-coated micropar-
ticles in TRIS buffer containing protein stabilizers
(0.02% solids), human hepatitis A virus in phosphate
buffer containing protein stabilizers (Titre ≥3,000, the
virus was inactivated with formaldehyde), an antibody to
hepatitis A virus (mouse, monoclonal), alkaline phos-
phatase conjugate in TRIS buffer containing protein sta-
bilizers (0.9 μg/mL), specimen diluent containing
sodium chloride in TRIS buffer, sodium azide, and anti-
microbial agents.
Determination of the detection limit of the ICA and the
MEIA
We selected 3 sets of 6 sera with high titres of anti-
HAV IgM, which were induced by infections with HAV
of 3 different genotypes (IA, IB, IIIA) identified through
molecular genotyping. The sera were diluted with phos-
phate-buffered saline (PBS) to 10-fold serial dilutions
ranging from 10
-1 to 10
-5. For a comparison of the
detection limits, we performed both the ICA and MEIA
using 5 serial dilutions of the 6 sera infected with HAV.
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